media – Page 626 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Gates streams $50m into Britain’s Dementia Discovery Fund

British venture the Dementia Discovery Fund (DDF) has received a $50 million investment from Bill Gates, to help fuel progress toward disease-modifying therapies for Alzheimer’s disease.
- Source: Pharmatimes
- 845
- November 14, 2017
Alzheimer's Market Views therapy
Study reveals how a very low calorie diet can reverse type 2 diabetes

In a new study, a Yale-led research team uncovers how a very low calorie diet can rapidly reverse type 2 diabetes in animal models. If confirmed in people, the insight provides potential new drug targets for treating this common chronic disease, said the researchers.
- Source: Medicalxpress
- 548
- November 14, 2017
calorie chronic diabetes Researches
Amgen makes regenerative medicine play, backing $25M Fortuna round to move neural stem cells into the clinic

Amgen’s VC wing has invested in Fortuna Fix to help move autologous neural stem cells into the clinic. The $25 million series B sets regenerative medicine startup Fortuna up to move candidates against Parkinson’s disease and spinal cord injury to clinical trials next year.
- Source: Fiercebiotech
- 572
- November 14, 2017
Amgen autologous neural stem cells Series
Why head and face pain causes more suffering

Hate headaches? The distress you feel is not all in your—well, head. People consistently rate pain of the head, face, eyeballs, ears and teeth as more disruptive, and more emotionally draining, than pain elsewhere in the body. Duke University scientists have discovered how the brain’s wiring makes us suffer more from head and face pain. The answer may lie not just in what is reported to us by the five senses, but in how that sensation makes us feel emotionally. The team found that sensory neurons that serve the head and face are wired directly into one of the brain’s principal emotional signaling hubs. Sensory neurons elsewhere in the body are also connected to this hub, but only indirectly. The results may pave the way toward more effective treatments for pain mediated by the craniofacial nerve, such as chronic headaches and neuropathic face pain. “Usually doctors focus on treating the sensation of ...
- Source: medicalxpress
- 497
- November 14, 2017
headache sensory neurons
Apps with social media features speed treatment in teen concussions

Research shows that teenagers who used a mobile health app once a day in conjunction with medical care improved concussion symptoms.
- Source: digitalcommerce360
- 640
- November 13, 2017
brain concussion health apps Researches
Do Children’s Antibiotics Lead to Type 1 Diabetes or Celiac Disease?

In a recent study, researchers investigated whether there is a link between children’s antibiotics and the rise of autoimmune diseases such as type 1 diabetes and celiac disease.
- Source: medicalnewsbulletin
- 633
- November 13, 2017
antibiotics autoimmune celiac diabetes Researches
Novartis posts eye drug data amid play for Eylea’s turf

Novartis’s bid to move in on Bayer’s and Regeneron’s eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker’s new RTH258 drug showed less disease activity than those on its rivals’ drug Eylea.
- Source: reuters
- 448
- November 13, 2017
active disease AMD Company Insight RTH258
Robots and AI Will Take Over These 3 Medical Niches First

We’re no stranger to robotics in the medical field. Robot-assisted surgery is becoming more and more common. Many training programs are starting to include robotic and virtual reality scenarios to provide hands-on training for students without putting patients at risk.
- Source: singularityhub
- 512
- November 13, 2017
Artificial Intelligence Market Views robotics surgery
Shooting for a new standard on osteoarthritis, Merck KGaA outlines promising data for a potential game-changer

Merck KGaA’s pharma group is taking one more step in a long journey toward rehabbing its rep in the R&D field this weekend. Company execs turned up at the ACR scientific conference in San Diego to roll out a promising look at some key Phase II osteoarthritis data — which comes with a critical caveat.
- Source: Endpts
- 652
- November 13, 2017
Merck osteoarthritis R&D sprifermin
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

Seattle Genetics, Inc. (SGEN) announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and MF are the most common subtypes of cutaneous T-cell lymphoma (CTCL).
- Source: finance.yahoo
- 486
- November 13, 2017
ADCETRIS anaplastic large cell lymphoma FDA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.